This addition highlights our commitment to meeting market needs and providing high-quality over the-counter solutions for our customers
This marks the first regulatory approval worldwide for nasally-delivered epinephrine
Collaboration with KNAUER to streamline and improve the scale-up of LNP formulations
Gross profit was Rs. 328.8 crore, up by 27.8% YoY with a gross margin expansion of 418 bps to 55.7%
Capital expenditure expected to moderate to Rs. 5.6 billion in FY2025 from an estimated Rs. 7.6 billion in FY2024
The fresh funds will be used to enhance customer relationships, expand operations and develop state-of-the-art service
This project is supported by the Irish Government through IDA Ireland
Revenue from operations stood at Rs. 313.4 crore during Q1 FY25
This accelerates the clinical-to-commercial process timeline and enables customers to develop the right molecule
This strong performance was primarily on account of a one-time gain from the strategic collaboration between Biocon Biologics and Eris Lifesciences.
Subscribe To Our Newsletter & Stay Updated
